Table 1.
Characteristics of the patients
| n° | Age (year) | Gender | Duration of dialysis (years) | Cause of renal failure | Dialysis membrane | Modality of dialysis | Risks factors for dialysis hypotension |
|---|---|---|---|---|---|---|---|
| 1 | 45 | F | 9 | SLE | Polysufone (ARYLANE H4 - Hospal) | 4 h × 3/Week | Long duration of dialysis (9 years), SLE still active treated by steroïds and ciclosporin - Diastolic dysfunction |
| 2 | 91 | F | 2 | Atherosclerotic nephropathy | Diacetate (DICEA130-Baxter) | 3 h × 3/Week | Very old age, severe ischemic cardiopathy - Diastolic dysfunction |
| 3 | 67 | F | 6 | Interstitial nephrotoxic nephritis (Ciclosporin) | PMMA (BKF16-Toray) | 4 h × 3/Week | Cardiac graft for ten years-Diastolic dysfunction |
| 4 | 87 | M | 2 | Atherosclerotic nephropathy | Diacetate (DICEA 150-Baxter) | 3 h × 3/Week | Very old age, severe ischemic cardiopathy-Diastolic dysfunction |
| 5 | 76 | M | 3 | Diabetes melitus type II | Triacetate (TRICEA210-Baxter) | 4 h × 3/Week | Old age, diabetes, pace-maker, panhypotuitarism - Diastolic dvsfunction |
| 6 | 84 | F | 3 | Renal and urologic tuberculosis | Diacetate (DICEA 130-Baxter) | 3 h30 × 3/Week | Very old age, severe ischemic and valvular cardiopathy - Diastolic dysfunction |
| 7 | 71 | M | 5 | Atherosclerotic nephropathy | Chemically modified Acetate (SMC 170 - Bellco) | 4 × 3 h/Week | Old age, severe ischemic cardiopathy-Diastolic dysfunction |
| 8 | 72 | M | 1 | Myeloma | Triacetate (TRICEA210-Baxter) | 3 h30 × 3/Week | Old age, severe ischemic cardiopathy, arythmia secondary to atrial fibrillation - chemotherapy for myeloma - Diastolic dysfunction |
| 9 | 70 | F | 7 | Analgesic nephropathy | Diacetate (DICEA 130-Baxter) | 4 h × 3/Week | Old age, long duration of dialysis (7 years), arythmia secondary to atrial fibrillation-Diastolic dysfunction |
| 10 | 50 | F | 6 | Autosomic dominant polycystic kidney disease | PAN (NEPHRAL 300-Hospal) | 4 h × 3/Week | Binephrectomy - Diastolic dysfunction |